This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Sarpogrelate
Accession Number
DB12163
Type
Small Molecule
Groups
Investigational
Description

Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Sarpogrelate HydrochlorideFQN8N8QP1B135159-51-2POQBIDFFYCYHOB-UHFFFAOYSA-N
Categories
UNII
19P708E787
CAS number
125926-17-2
Weight
Average: 429.513
Monoisotopic: 429.215137722
Chemical Formula
C24H31NO6
InChI Key
FFYNAVGJSYHHFO-UHFFFAOYSA-N
InChI
InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)
IUPAC Name
4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid
SMILES
COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 2CNot AvailableHuman
U5-hydroxytryptamine receptor 2A
inverse agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabSarpogrelate may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolSarpogrelate may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Acetylsalicylic acid.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
AlteplaseSarpogrelate may increase the anticoagulant activities of Alteplase.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Aminosalicylic Acid.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Sarpogrelate.Approved
AncrodSarpogrelate may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Sarpogrelate.Investigational
AnistreplaseSarpogrelate may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanSarpogrelate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Apixaban.Approved
AprotininThe therapeutic efficacy of Sarpogrelate can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinSarpogrelate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanSarpogrelate may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinSarpogrelate may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the anticoagulant activities of Sarpogrelate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Balsalazide.Approved, Investigational
BatroxobinSarpogrelate may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminSarpogrelate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinSarpogrelate may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BeraprostBeraprost may increase the anticoagulant activities of Sarpogrelate.Investigational
BivalirudinSarpogrelate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseSarpogrelate may increase the anticoagulant activities of Brinase.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Sarpogrelate.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Sarpogrelate.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Sarpogrelate.Approved
CaplacizumabSarpogrelate may increase the anticoagulant activities of Caplacizumab.Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Carbaspirin calcium.Experimental, Investigational
CertoparinSarpogrelate may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolCilostazol may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
Citric AcidSarpogrelate may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Sarpogrelate.Approved
CloricromenSarpogrelate may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneSarpogrelate may increase the anticoagulant activities of Clorindione.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Collagenase clostridium histolyticum.Approved, Investigational
Dabigatran etexilateSarpogrelate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinSarpogrelate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSarpogrelate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSarpogrelate may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Dersalazine.Investigational
DesirudinSarpogrelate may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseSarpogrelate may increase the anticoagulant activities of Desmoteplase.Investigational
DextranSarpogrelate may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DicoumarolSarpogrelate may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Diflunisal.Approved, Investigational
DiphenadioneSarpogrelate may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Sarpogrelate.Approved
DitazoleSarpogrelate may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaSarpogrelate may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidSarpogrelate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSarpogrelate may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinSarpogrelate may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
EplivanserinSarpogrelate may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Sarpogrelate.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Sarpogrelate.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
Ethyl biscoumacetateSarpogrelate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidSarpogrelate may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinSarpogrelate may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneSarpogrelate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FondaparinuxSarpogrelate may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumSarpogrelate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateSarpogrelate may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Sarpogrelate.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Guacetisal.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Hemoglobin crosfumaril.Experimental
HeparinSarpogrelate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineSarpogrelate may increase the anticoagulant activities of Higenamine.Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Sarpogrelate.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sarpogrelate.Approved
IbudilastIbudilast may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational, Nutraceutical
IdraparinuxSarpogrelate may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Sarpogrelate.Investigational
IloprostIloprost may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
IndobufenSarpogrelate may increase the anticoagulant activities of Indobufen.Investigational
KetanserinKetanserin may increase the anticoagulant activities of Sarpogrelate.Investigational
LepirudinSarpogrelate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanSarpogrelate may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Sarpogrelate.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Sarpogrelate.Experimental
MelagatranSarpogrelate may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Mesalazine.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Methyl salicylate.Approved, Vet Approved
MilrinoneMilrinone may increase the anticoagulant activities of Sarpogrelate.Approved
NadroparinSarpogrelate may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatSarpogrelate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Sarpogrelate.Investigational
NimesulideNimesulide may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Obinutuzumab.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Sarpogrelate.Approved, Nutraceutical
OtamixabanSarpogrelate may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelSarpogrelate may increase the anticoagulant activities of Ozagrel.Investigational
ParnaparinSarpogrelate may increase the anticoagulant activities of Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateSarpogrelate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Sarpogrelate.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Sarpogrelate.Approved, Investigational
PhenindioneSarpogrelate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonSarpogrelate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Phenyl aminosalicylate.Approved
PicotamideSarpogrelate may increase the anticoagulant activities of Picotamide.Experimental
PrasugrelPrasugrel may increase the anticoagulant activities of Sarpogrelate.Approved
Protein CSarpogrelate may increase the anticoagulant activities of Protein C.Approved
Protein S humanSarpogrelate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSarpogrelate may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Sarpogrelate.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Sarpogrelate.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Sarpogrelate.Approved, Experimental, Investigational
ReteplaseSarpogrelate may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinSarpogrelate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Sarpogrelate.Approved
RivaroxabanSarpogrelate may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneSarpogrelate may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Salicylic acid.Approved, Investigational, Vet Approved
SaruplaseSarpogrelate may increase the anticoagulant activities of Saruplase.Experimental
SelexipagSarpogrelate may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Sarpogrelate.Approved, Vet Approved
SRT501SRT501 may increase the anticoagulant activities of Sarpogrelate.Investigational
StreptokinaseSarpogrelate may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulodexideSarpogrelate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseSarpogrelate may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Sarpogrelate.Investigational
TicagrelorSarpogrelate may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Sarpogrelate.Approved
TinzaparinSarpogrelate may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolSarpogrelate may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Sarpogrelate.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Sarpogrelate.Approved
TositumomabThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Sarpogrelate.Approved
TreprostinilSarpogrelate may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TriflusalTriflusal may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Trolamine salicylate.Approved
TroxerutinSarpogrelate may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseSarpogrelate may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Sarpogrelate.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Sarpogrelate.Approved
WarfarinSarpogrelate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSarpogrelate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5160
PubChem Substance
347828455
ChemSpider
4976
BindingDB
50093789
ChEBI
135697
ChEMBL
CHEMBL52939
Wikipedia
Sarpogrelate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHigh Blood Pressure (Hypertension) / Peripheral Artery Disease (PAD)1
3CompletedPreventionCerebral Infarctions1
3CompletedTreatmentCoronary Artery Disease / Diabetes Mellitus (DM) / Renal Insufficiency,Chronic1
4CompletedTreatmentCoronary Artery Disease1
4RecruitingTreatmentAngina, Prinzmetal's1
4Unknown StatusPreventionChronic Kidney Disease (CKD)1
4Unknown StatusTreatmentDiabetic Nephropathies1
Not AvailableUnknown StatusTreatmentAtherosclerosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0109 mg/mLALOGPS
logP3.57ALOGPS
logP1.12ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.78ChemAxon
pKa (Strongest Basic)8.15ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area85.3 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity117.35 m3·mol-1ChemAxon
Polarizability46.89 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Anisoles / Fatty acid esters / Alkyl aryl ethers / Dicarboxylic acids and derivatives / Trialkylamines / Carboxylic acid esters / Amino acids / Carboxylic acids
show 4 more
Substituents
Stilbene / Phenoxy compound / Anisole / Methoxybenzene / Phenol ether / Alkyl aryl ether / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Benzenoid
show 19 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Muntasir HA, Takahashi J, Rashid M, Ahmed M, Komiyama T, Hossain M, Kawakami J, Nashimoto M, Nagatomo T: Site-directed mutagenesis of the serotonin 5-Hydroxytryptamine2c receptor: identification of amino acids responsible for sarpogrelate binding. Biol Pharm Bull. 2006 Aug;29(8):1645-50. [PubMed:16880620]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inverse agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Muntasir HA, Bhuiyan MA, Ishiguro M, Ozaki M, Nagatomo T: Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor. J Pharmacol Sci. 2006 Oct;102(2):189-95. Epub 2006 Oct 7. [PubMed:17031071]
  2. Aly SA, Hossain M, Bhuiyan MA, Nakamura T, Nagatomo T: Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate. J Pharmacol Sci. 2009 Aug;110(4):445-50. [PubMed:19672037]

Drug created on October 20, 2016 15:30 / Updated on May 02, 2018 01:39